BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
January 19, 2023 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The...
Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 16:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 08:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
Avricore Health Reports Third-Quarter 2022 Results
November 29, 2022 11:08 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today released its Q3 results which demonstrate significant revenue growth,...
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
November 07, 2022 07:00 ET
|
InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
October 24, 2022 11:03 ET
|
BioSig Technologies, Inc.
Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac...
BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022
October 12, 2022 10:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
$4.5+ Billion Artificial Heart Market Size to Exhibit CAGR of 15+% by 2028, Deep Dive Analysis of Key Players and Growth Opportunities
October 12, 2022 09:16 ET
|
The Insight Partners
New York, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners recently published a report on "Artificial Heart Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact...
BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base
October 07, 2022 09:35 ET
|
BioSig Technologies, Inc.
Westport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
October 04, 2022 07:00 ET
|
InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...